Hopman Mark, Chief Commercial Officer of Beta Bionics ($BBNX), made nine open market sales of company shares over the past year, totaling about $685,000. His latest sale occurred on March 4, 2026. These transactions rank 5,793rd out of 11,678 insiders by sale value, trailing the average of $8.6 million across 6.4 transactions per insider. Mark recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 2061 | $30.66 | 136,216.0000 | 44,024,631 | 1.49% | 0.00% |
| Dec. 2, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 856 | $29.34 | 138,277.0000 | 44,024,631 | 0.62% | 0.00% |
| Feb. 27, 2026 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 91520 | $0.00 | 91,520.0000 | 44,024,631 | 9999.99% | 0.21% |
| March 4, 2026 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 353 | $11.57 | 139,133.0000 | 44,024,631 | 0.25% | 0.00% |
| Feb. 27, 2026 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 58749 | $0.00 | 58,749.0000 | 44,024,631 | 9999.99% | 0.13% |
| Feb. 27, 2026 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Common Stock | 109105 | $0.00 | 140,320.0000 | 44,024,631 | 349.53% | 0.25% |
| March 2, 2026 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 834 | $12.36 | 139,486.0000 | 44,024,631 | 0.59% | 0.00% |
| Sept. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 6818 | $19.97 | 31,215.0000 | 43,348,840 | 17.93% | 0.02% |
| Sept. 5, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 11411 | $20.56 | 31,215.0000 | 43,348,840 | 26.77% | 0.03% |
| Sept. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Common Stock | 656 | $5.10 | 33,940.0000 | 43,348,840 | 1.97% | 0.00% |
| Sept. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Common Stock | 4093 | $5.10 | 38,033.0000 | 43,348,840 | 12.06% | 0.01% |
| Sept. 5, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Common Stock | 11411 | $5.10 | 42,626.0000 | 43,348,840 | 36.56% | 0.03% |
| Sept. 5, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Employee Stock Option (right to buy) | 11411 | $0.00 | 21,725.0000 | 43,348,840 | 34.44% | 0.03% |
| Sept. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Employee Stock Option (right to buy) | 4093 | $0.00 | 33,136.0000 | 43,348,840 | 10.99% | 0.01% |
| Sept. 4, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Employee Stock Option (right to buy) | 656 | $0.00 | 66,428.0000 | 43,348,840 | 0.98% | 0.00% |
| Sept. 2, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 848 | $18.86 | 33,284.0000 | 43,348,840 | 2.48% | 0.00% |
| Aug. 19, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Common Stock | 16158 | $5.10 | 50,290.0000 | 43,348,840 | 47.34% | 0.04% |
| Aug. 19, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 16158 | $16.61 | 34,132.0000 | 43,348,840 | 32.13% | 0.04% |
| Aug. 19, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | M | Employee Stock Option (right to buy) | 16158 | $0.00 | 67,084.0000 | 43,348,840 | 19.41% | 0.04% |
| June 2, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 551 | $18.15 | 34,211.0000 | 43,348,840 | 1.59% | 0.00% |
| June 2, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 238 | $17.03 | 34,762.0000 | 43,348,840 | 0.68% | 0.00% |
| June 2, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | S | Common Stock | 79 | $18.69 | 34,132.0000 | 43,348,840 | 0.23% | 0.00% |
| Feb. 27, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 52000 | $0.00 | 52,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Common Stock | 35000 | $0.00 | 35,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 37229 | $0.00 | 37,229.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 83242 | $0.00 | 83,242.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 47775 | $0.00 | 47,775.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 17765 | $0.00 | 17,765.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 39424 | $0.00 | 39,424.0000 | 0 | 9999.99% | 0.00% |
| Jan. 29, 2025 | Beta Bionics, Inc. | $BBNX | Hopman Mark | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 47775 | $0.00 | 47,775.0000 | 0 | 9999.99% | 0.00% |